Selective AhR Modulation by Tapinarof Reprograms Microglial Inflammation through the AhR-Nrf2 Axis.

Authors

Rana M El-Baz, Nahla Waheed, Anwar Abdelnaser

Published in

Toxicology letters. Pages 113184. Aug 20, 2026. Epub Aug 20, 2026.

Abstract

Neuroinflammation is a key contributor to neurodegenerative disease progression, driven by chronic microglial activation. The aryl hydrocarbon receptor (AhR) has emerged as an important regulator of inflammatory and antioxidant responses in microglia; however, AhR activation can produce divergent outcomes depending on the activating ligand. This study aimed to compare the effects of tapinarof, a bacteria-derived, nonsteroidal small-molecule therapeutic AhR agonist with immunomodulatory and antioxidant activity, with those of the classical environmental ligand benzo[a]pyrene (B[a]P) on inflammatory and antioxidant signaling in activated microglial cells. Using lipopolysaccharide (LPS)-stimulated SIM-A9 microglia, cell viability, nitric oxide production, time- and concentration-dependent gene expression, cytokine secretion, and pathway-specific knockdown of AhR and nuclear factor erythroid 2-related factor 2 (Nrf2) were assessed. Our results showed that tapinarof significantly reduced LPS-induced nitrite production and suppressed key pro-inflammatory genes while promoting selected Nrf2-associated antioxidant markers. In contrast, B[a]P did not attenuate nitric oxide production, showed weaker inhibition of inflammatory gene expression, and induced cytotoxicity at high concentration despite activating canonical AhR targets. Gene-silencing experiments showed that the effects of tapinarof were partly AhR-dependent and involved functional crosstalk with Nrf2. In conclusion, the present study demonstrates that AhR activation is ligand- and context-dependent in activated microglia and supports further evaluation of selective AhR modulation as an approach for limiting microglial inflammatory responses.

PMID:
42624441
Bibliographic data and abstract were imported from PubMed on 21 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.